These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 20405180)

  • 1. Cell death modulation by intravenous immunoglobulin.
    von Gunten S; Simon HU
    J Clin Immunol; 2010 May; 30 Suppl 1():S24-30. PubMed ID: 20405180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous immunoglobulin preparations contain anti-Siglec-8 autoantibodies.
    von Gunten S; Vogel M; Schaub A; Stadler BM; Miescher S; Crocker PR; Simon HU
    J Allergy Clin Immunol; 2007 Apr; 119(4):1005-11. PubMed ID: 17337295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural anti-Siglec autoantibodies mediate potential immunoregulatory mechanisms: implications for the clinical use of intravenous immunoglobulins (IVIg).
    von Gunten S; Simon HU
    Autoimmun Rev; 2008 Jun; 7(6):453-6. PubMed ID: 18558361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dimeric IVIG contains natural anti-Siglec-9 autoantibodies and their anti-idiotypes.
    Schaub A; von Gunten S; Vogel M; Wymann S; Rüegsegger M; Stadler BM; Spycher M; Simon HU; Miescher S
    Allergy; 2011 Aug; 66(8):1030-7. PubMed ID: 21385183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations.
    Altznauer F; von Gunten S; Späth P; Simon HU
    J Allergy Clin Immunol; 2003 Dec; 112(6):1185-90. PubMed ID: 14657880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunologic and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin preparations.
    von Gunten S; Schaub A; Vogel M; Stadler BM; Miescher S; Simon HU
    Blood; 2006 Dec; 108(13):4255-9. PubMed ID: 16902148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variation of anti-Fas antibodies in different lots of intravenous immunoglobulin.
    Reipert BM; Stellamor MT; Poell M; Ilas J; Sasgary M; Reipert S; Zimmermann K; Ehrlich H; Schwarz HP
    Vox Sang; 2008 May; 94(4):334-41. PubMed ID: 18266779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway.
    Prasad NK; Papoff G; Zeuner A; Bonnin E; Kazatchkine MD; Ruberti G; Kaveri SV
    J Immunol; 1998 Oct; 161(7):3781-90. PubMed ID: 9759905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Granulocyte death regulation by naturally occurring autoantibodies.
    von Gunten S; Simon HU
    Adv Exp Med Biol; 2012; 750():157-72. PubMed ID: 22903673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Siglec-8 and Siglec-F, the new therapeutic targets in asthma.
    Farid SSh; Mirshafiey A; Razavi A
    Immunopharmacol Immunotoxicol; 2012 Oct; 34(5):721-6. PubMed ID: 22324980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous immunoglobulin preparations promote apoptosis in lipopolysaccharide-stimulated neutrophils via an oxygen-dependent pathway in vitro.
    Takeshita S; Tsujimoto H; Nakatani K
    APMIS; 2005 Apr; 113(4):269-77. PubMed ID: 15865608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Khalili B; Bahna SL
    Ann Allergy Asthma Immunol; 2006 Sep; 97(3):272-80; quiz 281-3, 320. PubMed ID: 17042130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxic epidermal necrolysis and intravenous immunoglobulin: a review.
    Trent J; Halem M; French LE; Kerdel F
    Semin Cutan Med Surg; 2006 Jun; 25(2):91-3. PubMed ID: 16908399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel mechanism for therapeutic action of IVIg in autoimmune blistering dermatoses.
    Michael D; Grando SA
    Curr Dir Autoimmun; 2008; 10():333-43. PubMed ID: 18460894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease?
    Siragam V; Brinc D; Crow AR; Song S; Freedman J; Lazarus AH
    J Clin Invest; 2005 Jan; 115(1):155-60. PubMed ID: 15630455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoantibodies purified from therapeutic preparations of intravenous immunoglobulins (IVIg) induce the formation of autoimmune complexes in normal human serum: a role in the in vivo mechanisms of action of IVIg?
    Lamoureux J; Aubin E; Lemieux R
    Int Immunol; 2004 Jul; 16(7):929-36. PubMed ID: 15159376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of the cellular immune system by intravenous immunoglobulin.
    Tha-In T; Bayry J; Metselaar HJ; Kaveri SV; Kwekkeboom J
    Trends Immunol; 2008 Dec; 29(12):608-15. PubMed ID: 18926775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The autoreactivity of therapeutic intravenous immunoglobulin (IVIG) preparations depends on the fractionation methods used.
    Djoumerska I; Tchorbanov A; Pashov A; Vassilev T
    Scand J Immunol; 2005 Apr; 61(4):357-63. PubMed ID: 15853919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding.
    French LE; Trent JT; Kerdel FA
    Int Immunopharmacol; 2006 Apr; 6(4):543-9. PubMed ID: 16504917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of action of intravenous immune globulin in immune-mediated diseases.
    Mouthon L; Kaveri SV; Spalter SH; Lacroix-Desmazes S; Lefranc C; Desai R; Kazatchkine MD
    Clin Exp Immunol; 1996 May; 104 Suppl 1():3-9. PubMed ID: 8625540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.